Valproic acid-induced encephalopathy in very long course treated patients.

Primary Objective: In patients receiving valproate (VPA) treatment, valproate induced-encephalopathy (VIE) is among the most serious adverse side-effects and hyperammonaemia is a frequent and well-recognized event. This report evaluates adult patients receiving VPA for several years.

Research Design: This study was conducted in adult patients receiving VPA for several years.